Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

NAVREF News Center

  • 17 Mar 2020 9:09 AM | Hawk Tran (Administrator)

    The Office of Research and Development (ORD) is pleased to announce a webinar scheduled for Thursday, March 19th, from 2:30-4:00pm EST.  Details can be found below:

    • Topic:  ORD Research Response to COVID-19
    • Date: Thursday, March 19th, 2020 
    • Time: 2:30 – 4:00pm EST
    • Purpose:  The purpose of this training is to provide an update on VA’s Office of Research and Development organizational and research activities in response to COVID-19.  The presenters will discuss strategies for handling research-related activities in the context of COVID-19 in the VA.
    • Presenters:
      • Rachel Ramoni, DMD, ScD – Chief Research and Development Officer (CRADO)
      • Wendy Tenhula, PhD – Deputy CRADO
      • Grant Huang, MPH, PhD – Deputy CRADO, Enterprise Optimization (Acting)
      • Molly Klote, MD – Director, Office of Research Protections, Policy and Education
    • Target Audience:  Research committee members, research office staff, compliance officers, and Investigator and study team members.
    • Software Requirements:  Be sure you have Adobe Flash installed on your computer We suggest you log on using chrome.
    • Recording:  This training will be recorded

    Please distribute this announcement within your facility to others who may benefit from this training. 

     

    You can find registration information for future ORPP&E training opportunities as well as recordings of past webinars on our cyberseminar webpage:   https://www.research.va.gov/programs/orppe/education/webinars/default.cfm

    Handouts will be sent out the morning of the scheduled training.

     

    Please email vhacoordregulatory@va.gov if you would like to be added to our training notification listserv.


  • 11 Mar 2020 12:51 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation Act provides $3 million (M) to the Department of Defense Bone Marrow Failure Research Program (BMFRP) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on BMF diseases. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The FY20 BMFRP Program Announcement and General Application Instructions for the following award mechanism are posted on the Grants.gov website.

    https://cdmrp.army.mil/funding/bmfrp

    Idea Development Award – Preproposal due date May 11, 2020

    Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from first faculty appointment (or equivalent) at the time of the application submission or

    Early Career Investigators:
    Independent investigators at the level of Assistant Professor (or equivalent) and less than 10 years from his/her first faculty appointment (or equivalent) at the time of application submission deadline are eligible.

    • Pre-application is required; full application submission is by invitation only.
    • Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure bone marrow failure (BMF).
    • Proposed research should have a high probability of revealing new avenues of investigation.
    • Research project should include well-formulated, testable hypothesis and a well-developed and articulated research approach.
    • Strong BMF research team.
    • May include relevant preliminary data.
    • Clinical trials will not be supported.
    • The maximum allowable funding for the entire period of performance is $325,000 in direct costs (plus indirect costs).
    • The maximum period of performance is 2 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for the award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 10 Mar 2020 4:50 PM | Hawk Tran (Administrator)

    NAVREF is seeking to hire a clinical trial facilitator to support the newly created Partnered Research Program at VA’s Office of Research and Development.  Please see the position description in our jobs section.  This will be a NAVREF position with a WOC appointment working for the manager of the Partnered Research Program (a VA position).  This will be a remote (virtual) position working 40-hours per week, Mon-Fri.  We’d like to hire and start as early as April 1, 2020.

    We are seeking someone with good understanding and familiarity with VA NPCs, VA research, clinical trials, and project management.  Please share within your organization, with colleagues, and with other qualified individuals. 

    All interested parties should submit a resume to Hawk Tran at htran@navref.org.  This announcement closes on March 20, 2020


  • 10 Mar 2020 11:28 AM | Hawk Tran (Administrator)

    As part of NAVREF’s mission to advance the success of the VA-affiliated research and education corporations, we host an annual conference and several workshops throughout the year. These meetings are essential opportunities to learn best practices, engage your peers, and build connections. However, we are also committed to the health and safety of our members, and we are always vigilant about monitoring the local conditions where these events are held.

    COVID-19 is a developing situation and, like all of you, we are monitoring it closely. We are continuing to confidently plan for the NAVREF Annual Conference September 13-16, 2020 in Washington DC, the NPC Essentials Workshop April 16-17, 2020, in Denver, and a potential Grants Management Workshop in July 2020. We currently have no plans to postpone or cancel either of the scheduled events.

    We remain in close contact with hotel representatives on sanitary, health, and other measures that should be in place at the facilities hosting these events. We continue to monitor guidelines from the World Health Organization, Centers for Disease Control and Prevention, and other pertinent public health organizations as part of our collective responsibility to focus on the facts and to act with common sense and sound judgment.  As part of our balanced approach, we are also evaluating our options for virtual presentation should this option be needed.

    Members are advised to check the NAVREF website. We will update it regularly as the situation evolves and make sure it contains links to reliable public health resources.

    We look forward to seeing some of you in Denver and all of you later this year in DC!

    Links Updated as of March 10, 2020: 

    Colorado COVID-19 Information:   https://www.denvergov.org/content/denvergov/en/environmental-health/news/coronavirus-info.html

    CDC COVID-19 Information: https://www.cdc.gov/coronavirus/index.html

    WHO COVID-19 Information: https://www.who.int/emergencies/diseases/novel-coronavirus-2019


  • 4 Mar 2020 3:43 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation provides $15 million (M) to the Department of Defense Autism Research Program (ARP) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    FY20 ARP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    https://cdmrp.army.mil/funding/arp

     

    Clinical Trial Award – preapplication due April 15, 2020

    Investigators at or above the level of Assistant Professor (or equivalent), or

    Early-Career Investigator Partnering Principal Investigator (PI) Option: Investigators at or above the level of Assistant Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:

    • Must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
    • Is no more than 7 years from the receipt of a terminal degree
    • Has the freedom to commit at least 50% time to the project

    Supports research with the potential to have a major impact on the treatment and/or management of ASD.

    Applications in the following areas are strongly encouraged:

    • Dissemination/implementation of clinically validated interventions
    • Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions.
    • Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions.
    • Improve diagnosis and access to services across the life span
    • Interventions promoting success in key transitions to adulthood for individuals living with ASD
    • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
    • Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services
    • Understanding heterogeneity in treatment response

    Preliminary data relevant to the proposed clinical trial are required.

    Pre-application is required; application submission is by invitation only.

    Early-Career Investigator Partnering PI Option supports the development of young investigators pursuing or wishing to pursue a career in ASD clinical trial research.

    The maximum allowable funding for the entire period of performance is $2,000,000 in direct costs (plus indirect costs).

    Maximum period of performance is 4 years.

    Early-Career Investigator Partnering PI Option:

    The maximum allowable funding for the entire period of performance is $2,300,000 for direct costs (plus indirect costs).

    Maximum period of performance is 4 years.

    Clinical Translational Research Award – preapplication due April 15, 2020

    Investigators at or above the level of Assistant Professor (or equivalent)

    • Supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of ASD.
    • Applications in the following areas are strongly encouraged:
      • Dissemination/implementation of clinically validated interventions
      • Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions.
      • Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions.
      • Improve diagnosis and access to services across the life span
      • Interventions promoting success in key transitions to adulthood for individuals living with ASD
      • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
      • Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services
      • Understanding heterogeneity in treatment response
    • Preliminary data relevant to the proposed project are required.
    • Pre-application is required; application submission is by invitation only.
    • The maximum allowable funding for the entire period of performance is $600,000 in direct costs (plus indirect costs).
    • Maximum period of performance is 3 years.

     

    Idea Development Award – preapplication due April 15, 2020

    Investigators at or above the level of Assistant Professor (or equivalent)

    Multiple PI Option:   Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award. 

    • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.
    • Applications in the following areas are strongly encouraged:
      • Test of implementation strategies to increases use of evidence-based practices
      • Development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
      • Assessment of novel therapeutics using valid preclinical models
      • Mechanisms of heterogeneous clinical expression of ASD
      • Environmental risk factors
      • Improve diagnosis across the life span
      • Factors promoting success in key transitions to independence for individuals living with ASD
      • Cultural and socioeconomic factors in treatment efficacy, delivery, and access to services
      • Mechanisms underlying sex differences in ASD diagnosis
      • Mechanisms underlying conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures)
      • Factors impacting quality of life during geographic relocation, such as military permanent change of station
      • Long-term treatment outcomes from previous clinical trials for ASD core symptoms or to alleviate co-occurring conditions
    • Preliminary data are required.
    • Multiple PI Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.
    • Pre-application is required; application submission is by invitation only.
    • The maximum allowable funding for the entire period of performance is $550,000 in direct costs (plus indirect costs).
    • Maximum period of performance is 3 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 2 Mar 2020 1:02 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Peer Reviewed Medical Research Program (PRMRP) to support to support medical research projects of clear scientific merit and direct relevance to military health.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The FY20 PRMRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.   

    The vision and mission of the PRMRP is improve the health, care, and well-being of all military Service members, Veterans, and beneficiaries by encouraging, identifying, selecting, and managing medical research projects of clear scientific merit and direct relevance to military health.

    Congressionally Directed Topic Areas:  All applications submitted to the PRMRP must address at least one of the FY20 PRMRP Congressionally directed topic areas.  The FY20 PRMRP Topic Areas are as follows:

    ·        Arthritis

    ·        Burn Pit Exposure

    ·        Chronic Migraine and Post-Traumatic Headache

    ·        Congenital Heart Disease

    ·        Constrictive Bronchiolitis

    ·        Diabetes

    ·        Dystonia

    ·        Eating Disorders

    ·        Emerging Viral Diseases

    ·        Endometriosis

    ·        Epidermolysis Bullosa

    ·        Familial Hypercholesterolemia

    ·        Fibrous Dysplasia

    ·        Focal Segmental Glomerulosclerosis

    ·        Food Allergies

    ·        Fragile X

    ·        Frontotemporal Degeneration

    ·        Guillain-Barré Syndromemorrhage Control

    ·        Hepatitis B

    ·        Hydrocephalus

    ·        Immunomonitoring of Intestinal Transplants

    ·        Inflammatory Bowel Diseases

    ·        Interstitial Cystitis

    ·        Metals Toxicology

    ·        Mitochondrial Disease

    ·        Musculoskeletal Health

    ·        Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

    ·        Myotonic Dystrophy

    ·        Nutrition Optimization

    ·        Pancreatitis

    ·        Pathogen-Inactivated Blood Products

    ·        Plant-Based Vaccines

    ·        Polycystic Kidney Disease

    ·        Pressure Ulcers

    ·        Pulmonary Fibrosis

    ·        Resilience Training

    ·        Respiratory Health

    ·        Rheumatoid Arthritis

    ·        Sleep Disorders and Restriction

    ·        Spinal Muscular Atrophy

    ·        Sustained Release Drug Delivery

    ·        Vascular Malformations

    ·        Women’s Heart Disease

    https://cdmrp.army.mil/funding/prmrp

    Discovery Award – Letter of Intent due April 16, 2020

    Postdoctoral fellow or clinical fellow (or equivalent) and above

    • Supports the exploration of a highly innovative new concept or untested theory.
    • Not intended to support the logical progression of an already established line of questioning.
    • Clinical trials will not be funded.
    • Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s).

    ·      Maximum of $200,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 2 years

    Focused Program Award – Preproposal due April 23, 2020

    Full Professor level or above (or equivalent)

    • Preproposal submission is required; application submission is by invitation only.
    • Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal.
    • Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
    • Projects may range from exploratory/
      hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.
    • Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.

    ·      Maximum of $7.2 million for direct costs (plus indirect costs)

    ·      Maximum period of performance is 4 years

    Investigator-Initiated Research Award – Preproposal due April 23, 2020

    Assistant Professor level or above (or equivalent)

    • Preproposal submission is required; application submission is by invitation only.
    • Supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
    • Partnering PI Option available.
    • Clinical trials will not be funded.

    ·      Maximum of $1.6 million for direct costs (plus indirect costs)

    ·      Maximum of $2 million for direct costs (plus indirect costs) for applications including a Partnering PI Option

    ·      Maximum period of performance is 4 years

    Technology/ Therapeutic Development Award – Preproposal due April 23, 2020

    Assistant Professor level or above (or equivalent)

    • Preproposal submission is required; application submission is by invitation only.
    • Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life.
    • Product-oriented (e.g., device, drug, clinical guidelines).  The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.
    • Clinical trials will not be funded.

    ·      Maximum of $4 million for direct costs (plus indirect costs

    ·      Maximum period of performance is 4 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact: 

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 28 Feb 2020 4:51 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriation provides $15 million (M) to the Department of Defense Autism Research Program (ARP) to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program’s Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    FY20 ARP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    https://cdmrp.army.mil/funding/arp

     

    Clinical Trial Award – preapplication due April 15, 2020

    Investigators at or above the level of Assistant Professor (or equivalent), or

    Early-Career Investigator Partnering Principal Investigator (PI) Option: Investigators at or above the level of Assistant Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:

    • Must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
    • Is no more than 7 years from the receipt of a terminal degree
    • ·         Has the freedom to commit at least 50% time to the project

    Supports research with the potential to have a major impact on the treatment and/or management of ASD.

    Applications in the following areas are strongly encouraged:

    • o    Dissemination/implementation of clinically validated interventions
    • o    Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions.
    • o    Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions.
    • o    Improve diagnosis and access to services across the life span
    • o    Interventions promoting success in key transitions to adulthood for individuals living with ASD
    • o    Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
    • o    Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services
    • o    Understanding heterogeneity in treatment response

    Preliminary data relevant to the proposed clinical trial are required.

    Pre-application is required; application submission is by invitation only.

    Early-Career Investigator Partnering PI Option supports the development of young investigators pursuing or wishing to pursue a career in ASD clinical trial research.

    The maximum allowable funding for the entire period of performance is $2,000,000 in direct costs (plus indirect costs).

    Maximum period of performance is 4 years.

    Early-Career Investigator Partnering PI Option:

    The maximum allowable funding for the entire period of performance is $2,300,000 for direct costs (plus indirect costs).

    Maximum period of performance is 4 years.

    Clinical Translational Research Award – preapplication due April 15, 2020

    Investigators at or above the level of Assistant Professor (or equivalent)

    • Supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of ASD.
    • Applications in the following areas are strongly encouraged:
    • o    Dissemination/implementation of clinically validated interventions
    • o    Behavioral, cognitive, and other non-pharmacological therapies for ASD core symptoms or to alleviate co-occurring conditions.
    • o    Pharmacological, genetic, and other biological treatments for ASD core symptoms or to alleviate co-occurring conditions.
    • o    Improve diagnosis and access to services across the life span
    • o    Interventions promoting success in key transitions to adulthood for individuals living with ASD
    • o    Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
    • o    Cultural, socioeconomic, and gender factors in diagnosis, treatment efficacy, delivery, and access to services
    • o    Understanding heterogeneity in treatment response
    • Preliminary data relevant to the proposed project are required.
    • ·         Pre-application is required; application submission is by invitation only.
    • The maximum allowable funding for the entire period of performance is $600,000 in direct costs (plus indirect costs).
    • ·         Maximum period of performance is 3 years.

     

    Idea Development Award – preapplication due April 15, 2020

    Investigators at or above the level of Assistant Professor (or equivalent)

    Multiple PI Option:   Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award. 

    • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.
    • Applications in the following areas are strongly encouraged:
      • Test of implementation strategies to increases use of evidence-based practices
      • Development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD across the life span and the continuum of care (i.e., primary care, urgent/emergent care, and disaster relief)
      • Assessment of novel therapeutics using valid preclinical models
      • Mechanisms of heterogeneous clinical expression of ASD
      • Environmental risk factors
      • Improve diagnosis across the life span
      • Factors promoting success in key transitions to independence for individuals living with ASD
      • Cultural and socioeconomic factors in treatment efficacy, delivery, and access to services
      • Mechanisms underlying sex differences in ASD diagnosis
      • Mechanisms underlying conditions co-occurring with ASD (e.g., sleep disturbances, gastrointestinal issues, inflammation, aggression, depression, anxiety, attention deficit, seizures)
      • Factors impacting quality of life during geographic relocation, such as military permanent change of station
      • Long-term treatment outcomes from previous clinical trials for ASD core symptoms or to alleviate co-occurring conditions
    • Preliminary data are required.
    • Multiple PI Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.
    • Pre-application is required; application submission is by invitation only.
    • The maximum allowable funding for the entire period of performance is $550,000 in direct costs (plus indirect costs).
    • ·         Maximum period of performance is 3 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 25 Feb 2020 3:05 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Epilepsy Research Program (ERP) to understand the causative links between traumatic brain injury (TBI) and epilepsy so that post-traumatic epilepsy (PTE) will be both preventable and treatable.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

    The ERP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 ERP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released. 

    Applications submitted to the FY20 ERP should address one or more of the following Focus Areas.  An application that proposes research outside of the FY20 Focus Areas is acceptable, as long as the applicant provides a strong rationale.  The Focus Areas will be mechanism-specific.

    • Innovative Research:  Tools intended to better inform or improve upon how PTE research can be performed:
      • Hardware and/or software platforms that will improve seizure detection, characterization, or diagnosis
      • Bioinformatics strategies, to include machine learning, that will improve access, annotation, curation, and visualization of large and novel datasets from single or multiple sources
      • Development of new models or better characterization of existing etiologically relevant models for PTE
      • Improved characterization of the circuits involved in PTE
      • Validate targets of post-traumatic epileptogenesis or established PTE
    • Markers and Mechanisms:  Identifying markers or mechanisms via preclinical models that address PTE, which may include the following:
      • Biomarkers
      • Treatment
      • Prevention
      • Diagnosis
      • Prognosis
      • Comorbidity
    • Epidemiology:  Epidemiological characterization of PTE following TBI, which may include the following:
      • Risk factors such as demographics, genetics, anatomy, pathology, or type of injury
      • Outcomes including latency to epilepsy, comorbidities, and mortality
      • Pre-existing conditions including psychological and psychiatric risk factors
      • Treatment and healthcare outcomes research
      • Differentiation of PTE and psychogenic non-epileptic seizures (PNES)
    • Longitudinal Studies: Studies of the evolution of PTE, which may include the following:
      • Seizure frequency and semiology
      • Demographics, genetics, anatomy, pathology, or type of injury
      • Comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)
      • Latency between type of injury and PTE
      • Mortality
      • Treatment and healthcare outcomes research
    • Quality of Life: Studies focused on improving quality of life for individuals with PTE and their caregivers by addressing the following:
      • Psychosocial factors
      • Neuropsychological dysfunction (cognition and memory)
      • Behavioral health (anxiety, depression, post-traumatic stress disorder, impulsivity)
      • Wellness
      • Reducing stigma
      • Activities of daily living
      • Care gaps (adjunct programs, support groups, access to care)
      • Sleep disorders
      • Medication side effects

    https://cdmrp.army.mil/pubs/press/2020/20erppreann

    Idea Development Award

    Level I:  Funding Level I is intended to support early-career investigators ranging from the post-doctoral level (e.g. research associate, fellows, residents or equivalent) to within 3 years of their first independent faculty position. (mentor required)

    Level II:  The Principal Investigator (PI) must be an independent investigator at or above the level of Assistant Professor (or equivalent)

    Intent:  To support novel, innovative research to understand the magnitude and underlying mechanisms of PTE.

    • Level I is intended to support high-risk or high-gain research. Requires a mentor as part of the application.
    • Level II is intended to support a more mature, hypothesis-driven research project.

    The following Focus Areas are open to both Levels I and II:

    • Innovative Research
    • Markers and Mechanisms
    • Epidemiology
    • Longitudinal Studies

    Preliminary data, while not required, are encouraged for both levels.

    Clinical pharmacologic trials are specifically discouraged.

    Level I:

    ·      Maximum funding of $300,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    Level II:

    ·      Maximum funding of $500,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    Quality of Life Award

    Level I:  Funding Level I is intended to support early-career investigators ranging from the post-doctoral level (e.g. research associate, fellows, residents or equivalent) to within 3 years of their first independent faculty position. (mentor required)

    Level II:  The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Intent:  To support innovative research that improves the quality of life and care for individuals living with the common symptoms of PTE and/or their families and care providers, as related to the ERP’s mission.

    • Level I is intended to support high-risk or high-gain research. Requires a mentor as part of the application.
    • Level II is intended to support PIs at or above the level of assistant professor (or equivalent) from any field or discipline.

    The following Focus Areas are open to both Levels I and II:

    • Quality of Life

    Preliminary data, while not required, are encouraged for both levels.

    Clinical pharmacologic trials are specifically discouraged.

    Level I:

    ·      Maximum funding of $300,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    Level II:

    ·      Maximum funding of $500,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    Research Partnership Award

    The PI must be an independent investigator at or above the level of Assistant Professor (or equivalent).

    Intent:  To create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. 

    ·      Level I is intended to support preclinical or pre-validation research.

    ·      Level II is intended to support research requiring access to a patient cohort for a prospective study.

    Applications must include clearly stated plans for interactions between/among the partners.  The plans must include communication, coordination of research progress and results, and data sharing between all investigators and organizations participating in the project.

    The following Focus Areas are open to both Levels I and II:

    ·      Markers and Mechanisms

    ·      Epidemiology

    ·     Longitudinal Studies

    Preliminary data are required.

    Clinical pharmacologic trials are specifically discouraged

    Level I:

    ·      Maximum funding of $1,300,000 in total costs

    ·      Maximum period of performance is 3 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    Level II:

    ·      Maximum funding of $3,100,000 in total costs

    ·      Maximum period of performance is 4 years

    ·      Indirect costs may be proposed in accordance with the institution’s rate agreement

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ERP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 21 Feb 2020 1:03 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Multiple Sclerosis Research Program (MSRP) to support innovative and impactful research that addresses fundamental issues and gaps in Multiple Sclerosis (MS).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

     

    The MSRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity.  This pre-announcement should not be construed as an obligation by the Government.  The FY20 MSRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website.  Pre-application and application deadlines will be available when the Program Announcements are released. 

     

    https://cdmrp.army.mil/pubs/press/2020/20msrppreann

     

    Applications submitted to the FY20 MSRP must address at least one of the Focus Areas relevant to the award mechanism as described below.

     

    Clinical Trial Award (NEW!!!)

    Investigators at or above the level of Assistant Professor (or equivalent)

    ·        Pre-application submission is required; application submission is by invitation only.

    ·        Funds Phase I or II clinical trials relevant to MS; combinations of phases are permitted.

    ·        Funding must support a clinical trial and may not be used for preclinical studies.

    ·        Scientific rationale and preliminary data are required.

    ·         Must address at least one of the following Focus Areas:

    o    Promoting Repair, Neuroprotection, and Remyelination in MS

    Treatment of MS Symptoms

    ·       Maximum funding of $1,500,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 4 years.

     

    Exploration -Hypothesis Development Award

    Established Investigators:Independent investigators at or above the level of Assistant Professor (or equivalent) or

    New Investigators:

    ·        Independent investigators no more than  3 years from the start of their  faculty position

    ·        Must not have a Research Project Grant (R01) or similar non-mentored award

    UPDATED!!!

    ·        Pre-application submission is required; application submission is by invitation only.

    ·        Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field.

    ·        Preliminary data not required.

    ·        Clinical trials not allowed.

    ·         New Investigator Option supports applicants early in their faculty appointments.

    ·         Must address at least one of the following Focus Areas:

    o    Promoting Central Nervous System Regenerative Potential in Demyelinating Conditions

    o    Correlates of Disease Activity and Progression in MS

    o    Biology and Measurement of MS Symptoms

    Identify the Role of Factors in MS Etiology, Prodome, Onset, and Evolution, Including Repair Processes (NEW!!!)

    ·       Maximum funding of $150,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 2 years.

     

    Investigator-Initiated Research Award

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    ·        Pre-application submission is required; application submission is by invitation only.

    ·        Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care.

    ·        Preliminary data required.

    ·        Clinical trials not allowed.

    ·         Must address at least one of the following Focus Areas:

    o    Promoting Central Nervous System Regenerative Potential in Demyelinating Conditions

    o    Correlates of Disease Activity and Progression in MS

    o    Biology and Measurement of MS Symptoms

    Identify the Role of Factors in MS Etiology, Prodome, Onset, and Evolution, Including Repair Processes (NEW!!!)

    ·       Maximum funding of $600,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 3 years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the MSRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 20 Feb 2020 2:53 PM | Hawk Tran (Administrator)

    The FY20 Defense Appropriations Act provides funding to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

     

    The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunities.  This pre-announcement should not be construed as an obligation by the Government.  The FY20 LCRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released. 

     

    Applications submitted to the FY20 LCRP must address one or more of the following Areas of Emphasis:

     

    • Identify innovative strategies for the screening and early detection of lung cancer.
    • Understand the molecular mechanisms of initiation and progression to lung cancer.
    • Identify innovative strategies for prevention of the occurrence of lung cancer.
    • Identify innovative strategies for the treatment of lung cancer.
    • Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
    • Develop or optimize prognostic or predictive markers to assist with therapeutic decision-making.
    • Understand mechanisms of resistance to treatment (primary and secondary).
    • Understand contributors to lung cancer development other than tobacco.
    • Identify innovative strategies for lung cancer care delivery (disparities/clinical management/ surveillance/symptom management).

     

    Relevance to Military Health: The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families. Relevance to military health will be considered in determining relevance to the mission of the DHP and FY20 LCRP during programmatic review.   Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate relevance to military health:

     

    • Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
    • Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators
    • Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population
    • Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco

    https://cdmrp.army.mil/pubs/press/2020/20lcrppreann

     

    Concept Award

    Investigators at all academic levels

    ·     Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer.

    ·     Emphasis on innovation.

    ·     Clinical trials not allowed.

    ·     Preliminary data discouraged.

    ·     Relevance to military health strongly encouraged.

    ·       Maximum funding of $100,000 in direct costs (plus indirect costs).

    ·       Period of performance should not exceed 1 year.

     

    Career Development Award

    ·     Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment

    ·     Mentor:  At or above the level of Associate Professor (or equivalent); have a proven publication and funding record in lung cancer research

    ·     Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.

    ·     Clinical trials not allowed.

    ·     Preliminary data not required.

    ·     Relevance to military health strongly encouraged.

    ·       Maximum funding of $250,000 in direct costs (plus indirect costs).

    ·       Period of performance should not exceed 2 years.

     

    Idea Development Award

    Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or

    New Investigators:  Investigators that meet the following criteria by the application submission deadline date:

    ·        Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award

    ·        Are within 10 years of first faculty appointment (or equivalent)

    ·       Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.

    ·       Emphasis on innovation and impact.

    ·       New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.

     

    ·       Clinical trials not allowed.

    ·       Preliminary data required.

    ·       Relevance to military health strongly encouraged.

    ·       Maximum funding of $350,000 in direct costs (plus indirect costs).

    ·       Period of performance should not exceed 2 years.

     

     

    Investigator-Initiated Translational Research Award

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    ·       Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations.

    ·       This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:

    o    Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts

    o    Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug submission

    o    Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials

    ·       Preliminary data required.

    ·       Relevance to military health strongly encouraged.

    ·       Maximum funding of $400,000 in direct costs (plus indirect costs).

    ·       Period of performance should not exceed 2 years.

     

    Clinical Translational Research Partnership Award

    Investigators at or above the level of Assistant Professor (or equivalent)

    ·       Supports translational studies that include a clinical trial.

    ·       This mechanism is intended to fund partnerships between clinicians and laboratory scientists that accelerate ideas in lung cancer into clinical applications.

    o    One partner is strongly encouraged to be from either a military treatment facility or a Department of Veterans Affairs medical center.

    ·       Non-traditional partnerships are encouraged

    ·       Preliminary data required.

    ·       Relevance to military health strongly encouraged.

    ·       Patient research advocate involvement encouraged.

    ·       Biostatistician involvement encouraged.

    ·      Maximum combined funding of $1,200,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.


    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.orgprior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software